Faeth Therapeutics (FTH) Profit After Tax (2020 - 2026)

Faeth Therapeutics (FTH) has 7 years of Profit After Tax data on file, last reported at -$170.3 million in Q1 2026.

• Quarterly Profit After Tax fell 2380.49% year-over-year to -$170.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$184.5 million (down 533.01% YoY) and the FY2025 annual result came in at -$21.1 million, up 30.03% from the prior year.
• Profit After Tax eased to -$170.3 million in Q1 2026, from -$4.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$4.6 million in Q3 2025 to a low of -$170.3 million in Q1 2026.
• A 5-year average of -$17.9 million and a median of -$8.0 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 46.9% — and 2026, when it sank 2380.49%.
• Tracing FTH's Profit After Tax over 5 years: stood at -$11.4 million in 2022, then advanced by 29.44% to -$8.0 million in 2023, then rose by 0.29% to -$8.0 million in 2024, then soared by 40.8% to -$4.7 million in 2025, then plunged by 3498.08% to -$170.3 million in 2026.
• The last three Profit After Tax figures came in at -$170.3 million (Q1 2026), -$4.7 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.